New study challenges “gold standard” opioid treatment for cancer pain

Researchers examining the data on opioids for pain caused by cancer have found surprisingly large gaps in evidence regarding the true benefits of these medicines for cancer pain.

Ex-Kite leaders step in at Kyverna as CEO exits after landing year’s second-biggest IPO

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 17, 2024

Merck is on the lookout for more opportunities within immunology – Pharmaceutical Technology

Share this article Where Roche and Sanofi focused on acquiring their respective TL1A assets, MSD received additional tools and a biomarker library, which could allow

January 29, 2024

Vertex faces renewed calls to widen access to its cystic fibrosis medicines in poor countries

Several Latino advocacy groups and more than 100 clinicians from dozens of countries are lending their voices to an expanding campaign to pressure Vertex Pharmaceuticals

August 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.